DeltEx DRI

INB-200, our DeltEx DRI, is a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors. This is the first genetically engineered gamma-delta T cell therapy to be administered to patients and our initial indication is newly diagnosed Glioblastoma (GBM).
Since 2005 the standard of care treatment for GBM has been surgical resection followed by radiation and chemotherapy, referred to as the Stupp regimen. Currently, the majority of patients relapse in less than one year with very few patients surviving beyond five years. We engineered INB-200 to be resistant to alkylating chemotherapy such that it can be used as an adjuvant with the current standard-of-care to drive improved anti-tumor response. The Phase 1 repeat dose escalation clinical trial of INB-200 is being conducted at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.


DeltEx Allo

INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic bone marrow transplantation (HSCT). This is the first clinical trial of an expanded and activated allogeneic gamma delta T cell immunotherapy.
HSCT procedures have increased over the last 20 years, with over 9,000 patients treated in the United States in 2018. Our scientific founder, Dr. Lawrence Lamb, Ph.D., was the first to describe a survival benefit in HSCT patients with naturally elevated levels of gamma-delta T cells. INB-100 was designed to translate this observation into a treatment and provides donor derived allogeneic gamma-delta T cells to patients following their HSCT. We are conducting a Phase 1 dose escalation clinical trial of INB-100 at the University of Kansas Cancer Center.


DeltEx Allo DRI

INB-400, our DeltEx Allo DRI, is a preclinical product candidate expanding the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or “off-the-shelf” DeltEx DRI therapy. We aim to take the clinical results from the ongoing INB-200 and INB-100 clinical trials to provide the safety data to support an IND submission for INB-400. The INB-400 product candidate will be a genetically modified DeltEx allogeneic candidate with an initial indication in newly diagnosed GBM.



INB-300, our DeltEx DRI CAR-T, is a preclinical product candidate combining our expertise in gamma-delta T cells, our DRI technology and a novel CAR-directed against the Cholotoxin peptide. Chlorotoxin binds to GBM tumor cells and has been previously utilized as a tumor paint in this setting. Chlorotoxin can also bind to other solid tumors including lung, breast and prostate cancers, among others.

This video demonstrates the cytotoxicity of our DeltEx DRI CAR-T cells (clear) in vitro against glioblastoma cells that express green fluorescent protein (green). Our CAR-T cells work to efficiently swarm, attack, and eradicate the tumor cells and illustrate the direct killing action of these gamma-delta T cells.